Related Experiment Video

Updated: May 30, 2026

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

Published on: December 19, 2019

Carcinogenesis in the Pituitary Dwarf Mouse. The Response to Dimethylbenzanthracene Applied to the Skin

F Bielschowsky, M Bielschowsky

    British Journal of Cancer
    |July 21, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
    06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    Cell Population Analyses During Skin Carcinogenesis
    06:53

    Cell Population Analyses During Skin Carcinogenesis

    Published on: August 21, 2013

    Related Experiment Videos

    Last Updated: May 30, 2026

    Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
    04:12

    Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

    Published on: December 19, 2019

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
    06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    Cell Population Analyses During Skin Carcinogenesis
    06:53

    Cell Population Analyses During Skin Carcinogenesis

    Published on: August 21, 2013

    Related Concept Videos

    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

    Articles linked to this work by shared authors, journal, and citation graph.

    Osteosarcomas in NZBR/BI mice.

    Pathology·1979

    Abundant CD8+ tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets.

    British journal of cancer·2026

    From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma.

    British journal of cancer·2026

    Switches in alternatively spliced isoforms impact protein and drug interactions in melanoma, ovarian cancer, and acute myeloid leukemia.

    British journal of cancer·2026

    Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.

    British journal of cancer·2026

    A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study.

    British journal of cancer·2026

    Neoadjuvant chemotherapy as a bridge to surgery versus direct surgery following SEMS placement in obstructive left-sided colon cancer: a multicenter prospective cohort study.

    British journal of cancer·2026

    Chlorogenic Acid Derivative B11 Inhibits Glioma Proliferation by Targeting MST4 to Regulate Oxidative Stress.

    Molecular carcinogenesis·2026

    CNOT4 Suppresses Bladder Cancer Progression by Promoting Ubiquitination-Mediated Degradation of EIF2AK2 and Inhibiting Autophagy.

    Molecular carcinogenesis·2026

    Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey.

    The oncologist·2026

    Targeting RAS in pancreatic cancer.

    Cancer·2026

    Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors.

    Journal of the National Cancer Institute·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us